News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Start News Regulatory

Press releases

Regulatory

May 19, 2022

Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue

Regulatory

April 28, 2022

Egetis Therapeutics publishes prospectus relating to the Rights Issue

Regulatory

April 26, 2022

Interim report January-March 2022

Regulatory

April 20, 2022

Egetis Therapeutics’ 2021 annual report published

Regulatory

April 13, 2022

Bulletin from extraordinary shareholders’ meeting in Egetis Therapeutics AB and publication of timetable relating to the rights issue

Regulatory

March 21, 2022

NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS

Regulatory

March 21, 2022

Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million

Regulatory

February 17, 2022

Significant progress towards Emcitate® marketing applications in the US and Europe in 2023

Regulatory

January 18, 2022

Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US

Regulatory

December 13, 2021

Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com